Drug Profile

AEG 40826

Alternative Names: AEG40826; HGS-1029

Latest Information Update: 20 May 2016

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Aegera Therapeutics
Developer Human Genome Sciences; Pharmascience
Class Antineoplastics; Small molecules
Mechanism of Action Inhibitor of apoptosis protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

No development reported Solid tumours
Discontinued Lymphoma

Most Recent Events

20 May 2016 No recent reports on development identified- Phase-I for Solid tumours in Canada (IV)
12 Dec 2012 Pharmascience intends to initiate a phase Ib trial of AEG 40826 in the near future
12 Dec 2012 Pharmascience Inc. regains global rights to AEG 4086 as part of an agreed-upon termination of its oncology collaboration with Human Genome Sciences

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com